This protocol applies to patients with renal sarcoidosis who present with significant hypercalcemia — a total serum calcium exceeding 11 mg/dl — or with nephrolithiasis. This level of calcium elevation, or the presence of kidney stones, marks a threshold at which active management is indicated.
Corticosteroid therapy is the established first-line intervention for this degree of hypercalcemia or for sarcoidosis-associated nephrolithiasis. Treatment is initiated at a defined dose and then followed by a structured taper — the complete regimen, sequencing, and tapering schedule are detailed in the full protocol.
The primary target is a reduction in serum calcium. Response to the initiated therapy is expected to occur within the treatment course.
For more significant hypercalcemia (e.g. Ca >11 mg/dl) or nephrolithiasis, corticosteroid therapy is usually implemented at 20-40 mg daily.
Reduction in hypercalcemia usually occurs fairly quickly with steroid implementation, and some will attempt to taper the corticosteroids more quickly after 1-2 months.
View source ↗